Market Research Logo

Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Pipeline Review, H2 2016

Introduction
Global Markets Direct Report Coverage
Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) Overview
Therapeutics Development
Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Products under Development by Stage of Development
Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Products under Development by Therapy Area
Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Products under Development by Indication
Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Products under Development by Companies
Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Products under Development by Universities/Institutes
Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Companies Involved in Therapeutics Development
Ensemble Therapeutics Corporation
NeuroVive Pharmaceutical AB
Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Drug Profiles
cyclosporine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cyclosporine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVP-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVP-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVP-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVP-019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Cyclophilin D for Acute Pancreatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cyclophilin D for Cardiovascular and Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Dormant Projects
Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Discontinued Products
Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Featured News & Press Releases
Jun 07, 2016: NeuroVive announces CiPRICS study completes enrolment
Apr 28, 2016: NeuroVive’s R&D Team to Present Research Progress at Mitochondrial Medicine Conference
Mar 14, 2016: NeuroVive announces the CiPRICS study enrols 100 patients and reports favourable safety evaluation
Nov 19, 2015: NeuroVive reports favourable safety evaluation in Phase II acute kidney injury study
Nov 02, 2015: NeuroVive Pharmaceutical: NeuroVive Presents Findings Targeting Complex I Deficiency at World Mitochondria Congress
Oct 28, 2015: NeuroVive Aims to Find Path Forward in Antiviral Development Following Discontinuation of OCB-030 Preclinical Program by Arbutus
Aug 30, 2015: Cyclosporine Does Not Improve Outcomes After PCI
Jun 01, 2015: Neurovive Reports Topline Results of Phase III CIRCUS Study in Acute Myocardial Infarction
May 25, 2015: Neurovive Pharmaceutical: Topline Result of Phase III Study of Ciclomulsion in Acute Myocardial Infarction Expected This Quarter
May 07, 2015: Neurovive Pharmaceutical: Published Data Indicates Protective Effect of Cyclosporine in Patients with Stroke
Apr 27, 2015: FIrst Patient Enrolled in Clinical Phase II Study for Kidney Protection During Heart Surgery
Apr 21, 2015: Clinical Phase II Study with NeuroSTAT for Traumatic Brain Injury Passes Safety Evaluation
Apr 17, 2015: Development of NVP014 for the treatment of stroke enters new phase in collaboration with Isomerase Therapeutics
Dec 02, 2014: NeuroVive and Skane University Hospital initiate collaboration on clinical phase II study on kidney protection during heart surgery
Aug 14, 2014: Neurovive Pharmaceutical Announces Enrollment To Phase II Study On NeuroSTAT Continues
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Ensemble Therapeutics Corporation, H2 2016
Pipeline by NeuroVive Pharmaceutical AB, H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) - Pipeline Review, H2 2016’, provides in depth analysis on Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) targeted pipeline therapeutics.

The report provides comprehensive information on the Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape for Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8)
    • The report reviews Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved in Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) targeted therapeutics and enlists all their major and minor projects
    • The report assesses Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news and deals related to Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) targeted therapeutics
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand the targeted therapy areas and indications for Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8)
    • Identify the use of drugs for target identification and drug repurposing
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Peptidyl Prolyl Cis Trans Isomerase D (40 kDa Peptidyl Prolyl Cis Trans Isomerase or Cyclophilin 40 or Cyclophilin D or Rotamase D or PPID or EC 5.2.1.8) development landscape
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report

    ;